Bleeding severity as an important outcome in childhood immune thrombocytopenia

Pediatric Blood and Cancer

Volumn 60, Issue SUPPL.1, 2013, Pages

  Flores, Adolfo ^a   Buchanan, George R ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Bleeding severity; Bleeding severity instrument; Childhood immune thrombocytopenia (ITP); Therapeutic guidelines

Indexed keywords

CORTICOSTEROID;

BLEEDING; CHILD CARE; CHILDHOOD DISEASE; CLINICAL DECISION MAKING; DISEASE MARKER; DISEASE SEVERITY; HUMAN; LABORATORY TEST; MEDICAL LITERATURE; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PREDICTIVE VALUE; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

BIOLOGICAL MARKERS; CHILD; HEMORRHAGE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; PLATELET COUNT; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC;

EID: 84869205206     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24344     Document Type: Review

References (42)

1. Lusher JM, Zuelzer WW. Idiopathic thrombocytopenic purpura in childhood. J Pediatr 1966; 68: 971-979.
2. Benham ES, Taft LI. Idiopathic thrombocytopenic purpura in children: Results of steroid therapy and splenectomy. Aust Pediatr J 1972; 8: 311-317.
3. Blanchette VS, Turner C. Treatment of acute idiopathic thrombocytopenic purpura [Letter]. J Pediatr 1985; 326: 326-327.
4. Lammi AT, Lovric VA. Idiopathic thrombocytopenic purpura: An epidemiologic study. J Pediatr 1973; 83: 31-336.
5. McClure PD. Idiopathic thrombocytopenic purpura in children: Diagnosis and management. Pediatrics 1975; 55: 68-74.
6. Simons SM, Main CA, Yaish HM, et al. Idiopathic thrombocytopenic purpura in children. J Pediatr 1975; 87: 16-22.
7. Buchanan GR. Childhood acute idiopathic thrombocytopenic purpura: How many tests and how much treatment required? J Pediatr 1985; 106: 928-930.
8. Buchanan GR. The nontreatment of childhood idiopathic thrombocytopenic purpura. Eur J Pediatr 1987; 146: 107-112.
9. Buchanan GR. Overview of ITP treatment modalities in children. Blut 1989; 59: 96-104.
10. Buchanan GR. ITP: How much treatment is enough? Contemp Pediatr 1995; 12: 23-48.
11. Buchanan GR, Holtkamp CA. Prednisone therapy for children with newly diagnosed idiopathic thrombocytopenic purpura. A randomized clinical trial. Am J Pediatr Hematol Oncol 1984; 6: 355-361.
12. Imbach P, Barandun S, Baumgartner C, et al. High-dose intravenous gammaglobulin therapy of refractory, in particular idiopathic thrombocytopenia in childhood. Helv Paediatr Acta 1981; 36: 81-86.
13. Imbach P, Wagner HP, Berchtold W, et al. Intravenous immunoglobulin versus oral corticosteroids in acute immune thrombocytopenic purpura in childhood. Lancet 1985; 2: 464-468.
14. RhoD. WinRho SDF [package insert]. Winnipeg, Manitoba, Canada: Cangene Corporation; 1998.
15. Blanchette VS, Luke B, Andrew M, et al. A prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura. J Pediatr 1993; 123: 989-995.
16. Blanchette V, Imbach P, Andrew M, et al. Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet 1994; 344: 703-707.
17. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: A practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996; 88: 3-40.
18. Bolton-Maggs PH. Acute idiopathic thrombocytopenic purpura-Management in childhood. Blood 1997; 89: 1465; author reply 1466.
19. Buchanan GR, de Alarcon PA, Feig SA, et al. Acute idiopathic thrombocytopenic purpura-Management in childhood. Blood 1997; 89: 1464-1465; author reply 1466.
20. George JN, Davidoff F. Idiopathic thrombocytopenic purpura: Lessons from a guideline. Ann Intern Med 1997; 126: 317-3318.
21. Blanchette V, Bolton-Maggs P. Childhood immune thrombocytopenic purpura: Diagnosis and management. Hematol Oncol Clin North Am 2010; 24: 249-273.
22. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115: 168-186.
23. Vesely SK, Buchanan GR, Adix L, et al. Self-reported initial management of childhood idiopathic thrombocytopenic purpura: Results of a survey of members of the American Society of Pediatric Hematology/Oncology, 2001. J Pediatr Hematol Oncol 2003; 25: 130-133.
24. Bolton-Maggs P, Tarantino MD, Buchanan GR, et al. The child with immune thrombocytopenic purpura: Is pharmacotherapy or watchful waiting the best initial management? A panel discussion from the 2002 meeting of the American Society of Pediatric Hematology/Oncology. J Pediatr Hematol Oncol 2004; 26: 146-151.
25. Temple R. A regulatory authority's opinion about surrogate endpoints. Clinical medicine in drug evaluation. In: Nimmo WS, Tucker GT, editors. New York: Wiley; 1995.
26. Bucher HC, Guyatt GH, Cook DJ, et al. Users' guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. Evidence-Based Medicine Working Group. JAM 1999; 282: 771-778.
27. Neunert CE, Buchanan GR, Imbach P, et al. Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura. Blood 2008; 112: 4003-4008.
28. Medeiros D, Buchanan GR. Major hemorrhage in children with idiopathic thrombocytopenic purpura: Immediate response to therapy and long-term outcome. J Pediatr 1998; 133: 334-339.
29. Neunert CE, Buchanan GR, Blanchette V, et al. Relationships among bleeding severity, health-related quality of life, and platelet count in children with immune thrombocytopenic purpura. Pediatr Blood Cancer 2009; 53: 652-654.
30. Klaassen RJ, Blanchette VS, Barnard D, et al. Validity, reliability, and responsiveness of a new measure of health-related quality of life in children with immune thrombocytopenic purpura: The Kids' ITP Tools. J Pediatr 2007; 150: 510-515; 515.e1.
31. Carcao MD, Blanchette VS, Dean JA, et al. The Platelet function analyzer (PFA-100): A novel in vitro system for evaluation of primary haemostasis in children. Br J Haematol 1998; 101: 70-73.
32. Carcao MD, Blanchette VS, Stephens D, et al. Assessment of thrombocytopenic disorders using the platelet function analyzer (PFA-100). Br J Haematol 2002; 117: 961-964.
33. Thomson W. Popular Lectures and Addresses, Vol. I-III. London, UK: MacMillan and Co. 1891-1894.
34. Lacey JV, Penner JA. Management of idiopathic thrombocytopenic purpura in the adult. Semin Thromb Hemost 1977; 3: 160-174.
35. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
36. Bolton-Maggs PH, Moon I. Assessment of UK practice for management of acute childhood idiopathic thrombocytopenic purpura against published guidelines. Lancet 1997; 350: 620-623.
37. Buchanan GR, Adix L. Grading of hemorrhage in children with idiopathic thrombocytopenic purpura. J Pediatr 2002; 141: 683-688.
38. Khellaf M, Michel M, Schaeffer A, et al. Assessment of a therapeutic strategy for adults with severe autoimmune thrombocytopenic purpura based on a bleeding score rather than platelet count. Haematologica 2005; 90: 829-832.
39. Page LK, Psaila B, Provan D, et al. The immune thrombocytopenic purpura (ITP) bleeding score: Assessment of bleeding in patients with ITP. Br J Haematol 2007; 138: 245-248.
40. NCI. Common Terminology Criteria for Adverse Events (CTCAE) version 3. 0. National Cancer Institute, US 2006 (National Institutes of Health): http://ctep.info.nih.gov
41. Koreth R, Weinert C, Weisdorf DJ, et al. Measurement of bleeding severity: A critical review. Transfusion 2004; 44: 605-617.
42. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: Report from an international working group. Blood 2009; 113: 2386-2393.